Developing novel therapies for NASH
In this exclusive interview, Dr Hank Mansbach, Chief Medical Officer…
In this exclusive interview, Dr Hank Mansbach, Chief Medical Officer of 89bio discusses clinical development of FGF21 therapy to treat fatty liver disease.